JP2021169519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021169519A5 JP2021169519A5 JP2021119885A JP2021119885A JP2021169519A5 JP 2021169519 A5 JP2021169519 A5 JP 2021169519A5 JP 2021119885 A JP2021119885 A JP 2021119885A JP 2021119885 A JP2021119885 A JP 2021119885A JP 2021169519 A5 JP2021169519 A5 JP 2021169519A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- deficiency
- side effects
- butyl
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 62
- 230000000694 effects Effects 0.000 description 62
- 239000003814 drug Substances 0.000 description 50
- 230000005764 inhibitory process Effects 0.000 description 50
- 229940079593 drug Drugs 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
- 230000007547 defect Effects 0.000 description 36
- 230000004060 metabolic process Effects 0.000 description 32
- 230000007812 deficiency Effects 0.000 description 30
- 239000000126 substance Substances 0.000 description 30
- 125000002252 acyl group Chemical group 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 208000006443 lactic acidosis Diseases 0.000 description 23
- 125000000217 alkyl group Chemical group 0.000 description 21
- 229940088679 drug related substance Drugs 0.000 description 20
- 239000008186 active pharmaceutical agent Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000004065 mitochondrial dysfunction Effects 0.000 description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 16
- 238000007254 oxidation reaction Methods 0.000 description 16
- 238000011144 upstream manufacturing Methods 0.000 description 16
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 15
- 239000000758 substrate Substances 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 13
- 230000034659 glycolysis Effects 0.000 description 13
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 13
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 230000002438 mitochondrial effect Effects 0.000 description 12
- 230000003647 oxidation Effects 0.000 description 12
- 230000002265 prevention Effects 0.000 description 11
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 239000000470 constituent Substances 0.000 description 10
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 10
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 101710088194 Dehydrogenase Proteins 0.000 description 7
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 7
- -1 benzylcarbonyl Chemical group 0.000 description 7
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 6
- 230000003178 anti-diabetic effect Effects 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 201000007993 AGAT deficiency Diseases 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 4
- 206010058892 Carnitine deficiency Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000021075 Creatine deficiency syndrome Diseases 0.000 description 4
- 208000000561 Guanidinoacetate methyltransferase deficiency Diseases 0.000 description 4
- 108700016549 Guanidinoacetate methyltransferase deficiency Proteins 0.000 description 4
- 208000032242 L-Arginine:glycine amidinotransferase deficiency Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 description 4
- 208000035172 MERRF Diseases 0.000 description 4
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 4
- 108700017825 Short chain Acyl CoA dehydrogenase deficiency Proteins 0.000 description 4
- 108700005875 X-linked Creatine deficiency Proteins 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000035806 respiratory chain Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 0 CCCN(C(*)CCSC(CCC(O)=O)=O)C(*)=O Chemical compound CCCN(C(*)CCSC(CCC(O)=O)=O)C(*)=O 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 3
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000034091 X-linked creatine transporter deficiency Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000007950 acidosis Effects 0.000 description 3
- 208000026545 acidosis disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000002997 creatine transporter deficiency Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 3
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 3
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 3
- 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000036022 Alpers' disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 108700009893 Arginine-Glycine Amidinotransferase Deficiency Proteins 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 description 2
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 description 2
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 2
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 2
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 102000008013 Electron Transport Complex I Human genes 0.000 description 2
- 108010089760 Electron Transport Complex I Proteins 0.000 description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 description 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000006136 Leigh Disease Diseases 0.000 description 2
- 208000017507 Leigh syndrome Diseases 0.000 description 2
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 2
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- YMJSQPNVQRHZDW-UHFFFAOYSA-N (3,4-dichlorophenyl)hydrazine Chemical compound NNC1=CC=C(Cl)C(Cl)=C1 YMJSQPNVQRHZDW-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 241001022645 Chondria <beetle> Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010059396 Mitochondrial DNA depletion Diseases 0.000 description 1
- 208000013234 Pearson syndrome Diseases 0.000 description 1
- 102000005041 SLC6A8 Human genes 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 108010007169 creatine transporter Proteins 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000009732 tufting Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470190 | 2014-04-08 | ||
| DKPA201470190 | 2014-04-08 | ||
| JP2020018467A JP7229189B2 (ja) | 2014-04-08 | 2020-02-06 | 新規な細胞透過性サクシネート化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018467A Division JP7229189B2 (ja) | 2014-04-08 | 2020-02-06 | 新規な細胞透過性サクシネート化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021169519A JP2021169519A (ja) | 2021-10-28 |
| JP2021169519A5 true JP2021169519A5 (https=) | 2021-12-23 |
Family
ID=58804197
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561677A Active JP7082861B6 (ja) | 2014-04-08 | 2015-04-08 | 新規な細胞透過性サクシネート化合物 |
| JP2020018467A Active JP7229189B2 (ja) | 2014-04-08 | 2020-02-06 | 新規な細胞透過性サクシネート化合物 |
| JP2021119885A Pending JP2021169519A (ja) | 2014-04-08 | 2021-07-20 | 新規な細胞透過性サクシネート化合物 |
| JP2021119813A Pending JP2021169518A (ja) | 2014-04-08 | 2021-07-20 | 新規な細胞透過性サクシネート化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561677A Active JP7082861B6 (ja) | 2014-04-08 | 2015-04-08 | 新規な細胞透過性サクシネート化合物 |
| JP2020018467A Active JP7229189B2 (ja) | 2014-04-08 | 2020-02-06 | 新規な細胞透過性サクシネート化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021119813A Pending JP2021169518A (ja) | 2014-04-08 | 2021-07-20 | 新規な細胞透過性サクシネート化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11147789B2 (https=) |
| EP (2) | EP3129016B1 (https=) |
| JP (4) | JP7082861B6 (https=) |
| KR (1) | KR102322543B1 (https=) |
| CN (1) | CN106458957B (https=) |
| AU (2) | AU2015243346C9 (https=) |
| CA (1) | CA2944565C (https=) |
| CY (1) | CY1120650T1 (https=) |
| DK (1) | DK3129016T3 (https=) |
| EA (1) | EA035678B1 (https=) |
| ES (2) | ES2683860T3 (https=) |
| HR (1) | HRP20181126T1 (https=) |
| IL (1) | IL247904B (https=) |
| LT (2) | LT3391941T (https=) |
| MA (2) | MA44092B1 (https=) |
| MX (1) | MX378072B (https=) |
| PL (1) | PL3129016T3 (https=) |
| PT (2) | PT3129016T (https=) |
| RS (1) | RS57624B1 (https=) |
| SG (1) | SG11201607907PA (https=) |
| SI (1) | SI3129016T1 (https=) |
| SM (1) | SMT201800429T1 (https=) |
| TR (1) | TR201810411T4 (https=) |
| WO (1) | WO2015155231A1 (https=) |
| ZA (1) | ZA201606608B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3129016T3 (pl) * | 2014-04-08 | 2018-10-31 | Neurovive Pharmaceutical Ab | Nowe przepuszczalne dla komórek związki bursztynianu |
| MX2016012752A (es) * | 2014-04-08 | 2016-12-12 | Neurovive Pharmaceutical Ab | Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp). |
| SG11201607908QA (en) | 2014-04-08 | 2016-10-28 | Neurovive Pharmaceutical Ab | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation |
| WO2017060420A1 (en) * | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
| WO2017060418A1 (en) * | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases |
| WO2017060422A1 (en) * | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders |
| WO2017096270A1 (en) * | 2015-12-03 | 2017-06-08 | The Regents Of The University Of California | Methods for treating mitochondrial diseases |
| CA3113071A1 (en) * | 2018-10-11 | 2020-04-16 | Imbria Pharmaceuticals, Inc. | Tca cycle intermediates and methods of use thereof |
| CN112888419A (zh) * | 2018-10-11 | 2021-06-01 | 安布里亚制药公司 | 用于治疗和预防Leber遗传性视神经病变的组合物和方法 |
| CN109675037B (zh) * | 2019-01-25 | 2021-09-14 | 南方医科大学 | Atp及其受体在制备治疗自闭症药物中的应用 |
| IL288990B2 (en) * | 2019-06-19 | 2025-09-01 | Abliva Ab | Succinate drug meters, preparations containing the succinate drug meters and its uses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB756422A (en) * | 1950-09-14 | 1956-09-05 | Saint Gobain | Esters of urethanes of glycols and the manufacture thereof |
| NL6806584A (https=) * | 1965-09-20 | 1968-11-12 | ||
| FR2265355B1 (https=) | 1974-03-28 | 1977-11-04 | Blum Jean | |
| US5112953A (en) | 1989-12-29 | 1992-05-12 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
| DE4101158C2 (de) | 1991-01-14 | 1994-06-23 | Dainippon Ink & Chemicals | Wärmehärtbare Reaktionsharzgemische, Verwendung der erfindungsgemäßen Reaktionsharze zur Herstellung von Formkörpern und Beschichtungen |
| AU651758B2 (en) | 1992-02-07 | 1994-07-28 | Tsumura & Co. | Side-effect alleviant |
| JPH07331262A (ja) * | 1994-05-31 | 1995-12-19 | Tonen Corp | パティキュレート低減用添加剤及び該添加剤を用いたディーゼルエンジン用燃料組成物 |
| CN1222139A (zh) * | 1996-06-13 | 1999-07-07 | 里奥药物制品有限公司 | 多元醇琥珀酸酯及其药物制剂 |
| GB9612331D0 (en) * | 1996-06-13 | 1996-08-14 | Leo Pharm Prod Ltd | Chemical compounds |
| EP1100927A2 (en) * | 1998-07-02 | 2001-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for making polyketides using altered pks |
| AUPR059400A0 (en) * | 2000-10-06 | 2000-11-02 | Bar-Ilan University | Formaldehyde-releasing prodrugs |
| EP1401850A1 (en) * | 2001-06-20 | 2004-03-31 | Nuevolution A/S | Nucleoside derivatives for library preparation |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| KR100791844B1 (ko) | 2006-06-30 | 2008-01-07 | 주식회사유한양행 | 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법 |
| KR101069502B1 (ko) | 2006-10-31 | 2011-09-30 | (주)아모레퍼시픽 | 비만 및 당뇨병 개선용 경구용 조성물 |
| US20120308646A1 (en) * | 2007-01-18 | 2012-12-06 | Hesheng Zhang | Tetracyclic anthraquinones possessing anti-cancer properties |
| WO2008118948A1 (en) | 2007-03-26 | 2008-10-02 | Atherogenics, Inc. | Methods and compositions of derivatives of probucol for the treatment of diabetes |
| US8410139B2 (en) | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| JP2014024772A (ja) | 2012-07-25 | 2014-02-06 | Univ Of Tokyo | ミトコンドリアのａｔｐ産生能昂進剤 |
| ES2661009T3 (es) * | 2012-10-05 | 2018-03-27 | Neurovive Pharmaceutical Ab | Succinatos protegidos para mejorar la producción de ATP mitocondrial |
| MX2016012752A (es) | 2014-04-08 | 2016-12-12 | Neurovive Pharmaceutical Ab | Profarmacos de acido succinico para incrementar la produccion de adenosina trifosfato (atp). |
| SG11201607908QA (en) | 2014-04-08 | 2016-10-28 | Neurovive Pharmaceutical Ab | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation |
| PL3129016T3 (pl) * | 2014-04-08 | 2018-10-31 | Neurovive Pharmaceutical Ab | Nowe przepuszczalne dla komórek związki bursztynianu |
-
2015
- 2015-04-08 PL PL15714820T patent/PL3129016T3/pl unknown
- 2015-04-08 ES ES15714820.6T patent/ES2683860T3/es active Active
- 2015-04-08 PT PT15714820T patent/PT3129016T/pt unknown
- 2015-04-08 ES ES18175718T patent/ES2953522T3/es active Active
- 2015-04-08 CN CN201580021727.0A patent/CN106458957B/zh active Active
- 2015-04-08 CA CA2944565A patent/CA2944565C/en active Active
- 2015-04-08 SI SI201530356T patent/SI3129016T1/sl unknown
- 2015-04-08 MX MX2016012691A patent/MX378072B/es unknown
- 2015-04-08 LT LTEP18175718.8T patent/LT3391941T/lt unknown
- 2015-04-08 EP EP15714820.6A patent/EP3129016B1/en active Active
- 2015-04-08 TR TR2018/10411T patent/TR201810411T4/tr unknown
- 2015-04-08 RS RS20180921A patent/RS57624B1/sr unknown
- 2015-04-08 DK DK15714820.6T patent/DK3129016T3/en active
- 2015-04-08 KR KR1020167030753A patent/KR102322543B1/ko not_active Expired - Fee Related
- 2015-04-08 EP EP18175718.8A patent/EP3391941B1/en active Active
- 2015-04-08 AU AU2015243346A patent/AU2015243346C9/en not_active Ceased
- 2015-04-08 WO PCT/EP2015/057606 patent/WO2015155231A1/en not_active Ceased
- 2015-04-08 PT PT181757188T patent/PT3391941T/pt unknown
- 2015-04-08 US US15/128,480 patent/US11147789B2/en active Active
- 2015-04-08 SG SG11201607907PA patent/SG11201607907PA/en unknown
- 2015-04-08 SM SM20180429T patent/SMT201800429T1/it unknown
- 2015-04-08 MA MA44092A patent/MA44092B1/fr unknown
- 2015-04-08 EA EA201692017A patent/EA035678B1/ru not_active IP Right Cessation
- 2015-04-08 MA MA39855A patent/MA39855B1/fr unknown
- 2015-04-08 JP JP2016561677A patent/JP7082861B6/ja active Active
- 2015-04-08 LT LTEP15714820.6T patent/LT3129016T/lt unknown
-
2016
- 2016-09-19 IL IL247904A patent/IL247904B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06608A patent/ZA201606608B/en unknown
-
2018
- 2018-07-16 HR HRP20181126TT patent/HRP20181126T1/hr unknown
- 2018-08-27 CY CY181100892T patent/CY1120650T1/el unknown
- 2018-12-19 AU AU2018282308A patent/AU2018282308B2/en not_active Ceased
-
2020
- 2020-02-06 JP JP2020018467A patent/JP7229189B2/ja active Active
-
2021
- 2021-07-20 JP JP2021119885A patent/JP2021169519A/ja active Pending
- 2021-07-20 JP JP2021119813A patent/JP2021169518A/ja active Pending
- 2021-09-14 US US17/474,482 patent/US12310940B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021169519A5 (https=) | ||
| KR102745965B1 (ko) | 간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들 | |
| CN103998035B (zh) | 包含格列酮和nrf2激活剂的药物组合物 | |
| EP3138838A1 (en) | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | |
| EP4309738A2 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| JP2018536641A5 (https=) | ||
| JP2010526831A5 (https=) | ||
| EA030250B1 (ru) | Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции | |
| CA2341700A1 (en) | Compositions and methods for treatment of mitochondrial diseases | |
| US20250295676A1 (en) | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification | |
| EP3280405B1 (en) | Inhibitors and their uses | |
| JP2021527061A5 (https=) | ||
| JP2021527045A5 (https=) | ||
| CA3131128A1 (en) | Compounds and methods of deuterated xanomeline for treating neurological disorders | |
| CN114080227B (zh) | 包含o-环植物鞘氨醇-1-磷酸酯的用于预防或治疗帕金森氏病的组合物 | |
| WO2006003277A1 (fr) | Produits biaryl aromatiques, compositions les contenant et utilisation comme medicaments | |
| HUT70394A (en) | Substituted kynurenines and a process for the preparation of them and pharmaceutical compns. contg. them | |
| Nudelman | Dimeric drugs | |
| EP1745786B1 (fr) | Composés neuroprotecteurs et compositions pharmaceutiques les comprenant | |
| KR20200085278A (ko) | 공유 에피토프-칼레티쿨린 상호 작용의 소분자 억제제 및 사용 방법 | |
| SK281850B6 (sk) | Antimikrobiálne účinné zmesi obsahujúce aminokyseliny, liečivá s ich obsahom a ich použitie | |
| US8962891B2 (en) | Synthetic analogs of sphingolipids | |
| KR20200090816A (ko) | 우울증 및 편두통 치료용 신규 화합물 | |
| US20090247535A1 (en) | Use of ranolazine for non-cardiovascular disorders | |
| KR20230039680A (ko) | Hdac 억제 및 급성 신장 손상 후 신장 회복 향상에 사용하기 위한 ptba의 수용성 프로드러그 |